How much does the CEO of Biogen make?
Executive compensation for the chief executive officer guiding Black Hills Corporation (a regulated electric and natural gas utility serving customers across several Midwestern and Western states) reflects utility sector governance standards. Official corporate proxy statements filed with regulatory authorities indicate that top executive remuneration packages total approximately 5 million to 9 million US dollars annually. This comprehensive executive pay framework combines a competitive baseline annual cash salary of roughly 850,000 to 1,050,000 US dollars with performance-linked short-term cash incentive bonuses and multi-year equity stock awards designed to align executive leadership directly with grid modernization, clean energy integration, and reliable utility service.
Related FAQs
Public opinion among Jewish populations regarding the State of Israel is nuanced and depends significantly on geographic location, religious affiliation, and generational factors.
Yes, Bilibili collects user data, which is standard practice for digital platforms to provide and improve their services.
Biogen is widely regarded as a significant employer in the biotechnology industry, offering compensation packages that are generally competitive with other major pharmaceutical firms.
No, BioMarin Pharmaceutical does not pay a dividend.
BlackRock is a top institutional shareholder in the Brunswick Corporation. As of March 2026, BlackRock holds approximately 9.
Warren Buffett does not hold shares of Broadcom within Berkshire Hathaway's investment portfolio.
Bitcoin and other cryptocurrencies are treated primarily as property rather than fiat currency by major tax authorities like the US Internal Revenue Service.
Determining whether Biogen Inc. (traded under the ticker BIIB) is a sound investment involves weighing its established leadership in neuroscience and biotechnology against pipeline execution risks and shifting pharmaceutical revenue streams.
Evaluating whether Biogen Inc. (traded under the ticker BIIB) represents a favorable investment involves examining its prominent market position in neuroscience, biotechnology, and rare disease therapeutics.
Wall Street financial research analysts tracking Biogen Inc. (NASDAQ: BIIB) predominantly maintain a consensus "Hold" rating on the stock, accompanied by selective buy recommendations from institutional healthcare specialists.
Biogen has implemented targeted workforce rationalizations and localized headcount adjustments, primarily tied to operational restructuring programs, pipeline prioritization choices, and post-acquisition integration initiatives.